OmniSeq News
OmniSeq, Inc. to Participate in the NCI-MATCH Clinical Trial
BUFFALO, N.Y., July 31, 2018 (GLOBE NEWSWIRE) -- OmniSeq, Inc.® a leading innovator in molecular science, today announced it is participating as a CLIA-certified/accredited laboratory for the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision...
read more
OmniSeq & LabCorp Launch OmniSeq Advance℠ Assay
New test combines both targeted therapy and immune-oncology biomarkers in a single test with 99% actionability, providing benefits for the treatment of patients and the development of new therapies.ASCO, CHICAGO, ILLINOIS – June 1, 2018 – OmniSeq® , a CAP accredited,...
read moreHitachi High-Tech Participates in OmniSeq Series B and Secures Japanese Distribution Rights
BUFFALO, NEW YORK – April 12, 2018 – OmniSeq® , a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, announced today Hitachi High-Technologies Corporation (TOKYO: 8036, Hitachi High-Tech)’s participation in OmniSeq’s Series B financing...
read moreOmniSeq & LabCorp Launch Tumor-Only MSI NGS Assay
BUFFALO, NEW YORK – April 16, 2018 – OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global life sciences company, announced today the commercial launch of OmniSeq MSI NGS, a tumor-only,...
read moreOmniSeq Receives CAP Accreditation and Publishes Analytical Validation Paper
Important Achievements Validate OmniSeq’s High Quality Laboratory Practices and Immune Report Card Assay Buffalo, NY – NOVEMBER 9, 2017 – OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today that it...
read moreOmniSeq and LabCorp Sign Exclusive Distribution Agreement and Series B Funding Commitment
Marcia Eisenberg, Chief Scientific Officer of LabCorp Diagnostics, to Join OmniSeq’s Board of Directors BUFFALO, N.Y., Aug. 21, 2017 (GLOBE NEWSWIRE) -- OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today...
read moreLaunch of Immune Report Card
BUFFALO, N.Y., June 14, 2017 (GLOBE NEWSWIRE) -- OmniSeq, an innovation of Roswell Park Cancer Institute, announced today the commercial launch of Immune Report Card SM, the first immune profiling test designed to help oncologists select the best mono and...
read moreTumor Genetics & Cancer Research
Dr. Lucio Miele from LSU School of Medicine talks about the benefits of the recent partnership with OmniSeq on WVUE FOX 8 News in New Orleans
read moreOmniSeq Forms Clinical Evaluation Partnership with LSU Health New Orleans to Provide Comprehensive Genomic Profiling
NEW ORLEANS, LOUISANA – November 10, 2016 – Louisiana State University Health Sciences Center New Orleans ( LSU Health New Orleans) and Omniseq (OmniSeq®), a subsidiary of the Roswell Park Cancer Institute (RPCI), are now partnering to provide oncologists with...
read moreOmniSeq Presents Benefits of Immune Cancer Profiling at Association of Molecular Pathology (AMP) with Thermo Fisher Scientific
THERMO FISHER SCIENTIFIC (TMO) EXPANDS PORTFOLIO OF NEXT-GENERATION SEQUENCING CANCER RESEARCH ASSAYS New Oncomine products enable immune response analysis of the tumor microenvironment, interrogation of BRCA 1-2 genes, and liquid biopsy research using cell-free DNA...
read more
Follow Us on Twitter
Immune Report Card®: New Test Matches Patients With Immunotherapies Likely to Work Best | Roswell Park Comprehensive Cancer Center https://t.co/M3a34gfbQG
Proud that OmniSeq has met the rigorous standards needed to become an NCI-MATCH participating lab. Working hard with our colleagues at LabCorp to bring this testing to NCORP sites across the country! https://t.co/qUQTFidjek
OmniSeq Advance "All I Want": https://t.co/NwtMmpXspL via @YouTube
Excellent work being done at UCSD by @Dr_R_Kurzrock to incorporate transcriptomics and clinical trial matching!
"I’m not saying that on the basis of this one trial transcriptomics can become standard of care but the #WINTHER trial definitely suggests transcriptomics should be an important part of additional clinical trials" @Dr_R_Kurzrock
@WIN_Consortium #ASCO18 https://t.co/GSJ7pbu2Cq